Twentyeight-Seven Therapeutics
PrivateLast Round
Series A
Extension
May 10, 2019
Total Funding Raised
$82.75M
Company Overview
Redona Therapeutics is a biotechnology company that develops small molecule drugs targeting enzymes that regulate RNA and DNA processes to treat serious diseases like cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Twentyeight-Seven Therapeutics Comparables
Compare Twentyeight-Seven Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| STORM Therapeutics | 82% | |
| Accent Therapeutics | 81% | |
| Expansion Therapeutics | 81% |
Twentyeight-Seven Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 10, 2019 | ||||
| Series A | Sep 6, 2018 |
Key People
Founding team and executive leadership
Twentyeight-Seven Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series A |
| Vertex Ventures HC | Series A |
| MPM BioImpact | Series A |
| Osage University Partners | Series A Extension |
| Astellas Venture Management | Series A |
| Sofinnova Partners | Series A Extension |
| Longwood Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 149% MoM, from 437 to 1.1K.
- May 10, 2019
$18M round led by Sofinnova Partners
Twentyeight-Seven Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Twentyeight-Seven Therapeutics's valuation, stock price, and market status.
Is Twentyeight-Seven Therapeutics a public or private company?
Twentyeight-Seven Therapeutics is a private company.
What is the current stock price of Twentyeight-Seven Therapeutics?
Twentyeight-Seven Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Twentyeight-Seven Therapeutics worth (valuation)?
Valuation information for Twentyeight-Seven Therapeutics is not publicly available.
Can I buy Twentyeight-Seven Therapeutics stock?
Twentyeight-Seven Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Twentyeight-Seven Therapeutics's last funding round?
Twentyeight-Seven Therapeutics's most recent funding round was Series A Extension on May 9, 2019.
Who are the main investors in Twentyeight-Seven Therapeutics?
Key investors in Twentyeight-Seven Therapeutics include MPM Capital, Sofinnova Partners.
Will Twentyeight-Seven Therapeutics IPO soon?
No public IPO plans have been announced for Twentyeight-Seven Therapeutics.
How can I track Twentyeight-Seven Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Twentyeight-Seven Therapeutics's secondary market activity and sign up for updates.